DR. TANVI GUPTA

DR. MITHUN THULASIDAS, DR.AJITA SASIDHARAN, DR. PRADEEP BALAM

Abstract

Purpose: To assess the efficacy and safety of Ripasudil in patients with uncontrolled intraocular pressure (IOP) using ≥2 topical glaucoma drugs.

Methods: In this single-center prospective study, Ripasudil was added as adjunctive therapy to ongoing glaucoma therapy. Primary outcome was IOP measured on follow-up visits at 2 weeks, 1 month and 3 months. Secondary outcome included drug related side effects.

Results: 33 eyes of 30 patients were included. Mean IOP decreased significantly from 29.09 ± 6.54 to 20.18 ± 6.49 at 2 weeks (P<0.001) and 19.12 ± 4.93 at 3 months (P<0.001) after adding Ripasudil. Common side effect noted was conjunctival hyperemia (9%) which was transient. Conclusion: Ripasudil provided additional IOP-lowering effect in different glaucoma subtypes, when added to already existing yet inadequate maximum tolerated medical therapy, with maximum effect seen at 1 month and maintained up to 3 months. No significant side effect leading to withdrawal of the drug was noted.